MIF and myeloid sarcoma: Additional studies are also needed to better understand whether or not MIF may represent a promising biomarker for PD progression and, eventually, therapeutic response and in particular so since the finding may not be disease-specific as increased serum levels of MIF have also been reported in other neurological disorders, including AD and MS [20,21,23,24].